3Indexed trials
drug · Product Intelligence
Lenvatinib
Pipeline Intelligence
Lenvatinib: 3 indexed trials, 1 sponsors; 20 linked Orange Book patents and 4 FDA-linked events where matched.
1Sponsors
20Orange Book patent links
4FDA-linked events
Development evidence
NCT04305054Merck Sharp & Dohme LLC · parkinsonsPHASE1,PHASE2
NCT04736706Merck Sharp & Dohme LLC · parkinsonsPHASE3
NCT06036836Merck Sharp & Dohme LLC · parkinsonsPHASE2
FDA / patent evidence
12226409*PEDLENVIMA · app 2069472038-11-15
12226409LENVIMA · app 2069472038-05-15
12083112*PEDLENVIMA · app 2069472036-09-03
11090386*PEDLENVIMA · app 2069472036-08-23
12083112LENVIMA · app 2069472036-03-03
10259791*PEDLENVIMA · app 2069472036-02-26
11186547*PEDLENVIMA · app 2069472036-02-26
10407393*PEDLENVIMA · app 2069472036-02-26
11090386LENVIMA · app 2069472036-02-23
10259791LENVIMA · app 2069472035-08-26
10407393LENVIMA · app 2069472035-08-26
11186547LENVIMA · app 2069472035-08-26
Regulatory context
FDA_EXCLUSIVITYLENVIMA · PED2027-10-03
FDA_EXCLUSIVITYLENVIMA · M-142027-04-03
FDA_EXCLUSIVITYLENVIMA · ODE-1962025-08-15
FDA_APPROVALLENVIMA · 2015-02-13
FDA Orange Book coverage is U.S.-specific and is not a substitute for worldwide patent or regulatory review.